Israel's Health Ministry and Innovation Authority launched a regulatory sandbox on 9 July 2026, naming three companies — including Pulsenmore and Cordio Medical — to pilot high-autonomy clinical AI in real hospitals while regulators co-develop approval rules.
~1 million USD
Pulsenmore autonomous-ultrasound project budget
Details
Maturity
Pilot
Promoter
Israel Innovation Authority & Ministry of Health
Period
2026
Keywords
healthcare, AI regulation, medtech
Context
On 9 July 2026, Israel's Ministry of Health and the Israel Innovation Authority launched a national regulatory sandbox for high-autonomy healthcare AI, letting companies trial systems that perform some clinical tasks independently while regulators observe and build approval frameworks in parallel.
Objectives
Let high-autonomy clinical AI systems be trialled in real hospital settings while regulators co-develop approval rules for autonomy and clinical risk in parallel, rather than adopting rules before any real-world evidence exists.
Activities
Three companies were named to the first cohort: Pulsenmore, selected for an approximately $1 million project developing autonomous AI analysis of at-home pregnancy ultrasound scans with Beilinson Medical Center (Clalit Health Services); Cordio Medical, piloting voice-analysis-based home heart-failure monitoring with Tel Aviv Sourasky Medical Center (Ichilov Hospital); and a third participant trialling AI-assisted fetal-weight assessment with Hadassah's hospitals in Jerusalem.
Conclusions
The program is only weeks old at the time of this evaluation - no clinical outcome or accuracy data has yet been published, and its value here is the regulatory design (named ministries, defined clinical partners, budgeted pilots) rather than demonstrated results.
Implementation
Indicative cost
Medium (€50k–€500k)
Time to results
Medium (1–3 years)
Staffing & skills
Ministry of Health, Israel Innovation Authority, Named hospital partners: Beilinson Medical Center (Clalit), Tel Aviv Sourasky Medical Center (Ichilov), Hadassah hospitals
Conditions for success
Named clinical partner hospitals for each pilot company
Budgeted, ministry-approved pilot projects (e.g. ~$1M for Pulsenmore)
Joint leadership by both the health regulator and the innovation-funding agency
Common failure modes
No clinical outcome, accuracy, or usage data has yet been published
Approval framework for high-autonomy clinical AI is still being co-developed rather than pre-existing
Commonly funded by
National / regional programmes
Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.
Do you run this practice?
Claim it —
verified implementers get a public contact pathway and can propose corrections.
Data sources
Where this practice's information was retrieved from, and when.